Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
January 7, 2026
0
Rapport Therapeutics in the NEWS Today, January 07, 2026, Rapport Therapeutics, Inc. (RAPP) announced plans to initiate its Phase 3 program for RAP-219 in FOS in the second quarter of 2026 and expand its epilepsy portfolio with a new program in PGTCS. Additionally, the Company announced progress across its pipeline, including . . . This content is for paid subscribers. Please click here to subscribe or …